Neuland Laboratories Ltd

Neuland Laboratories Ltd is rated Buy by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 June 2026, providing investors with the latest insights into its performance and outlook.

Neuland Laboratories Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by a combination of technical indicators including MACD, RSI, Bollinger Bands, and moving averages, suggesting a strengthening price momentum amid a positive market backdrop for the pharmaceuticals and biotechnology sector.

Neuland Laboratories Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a transition from bullish to mildly bullish trends. Despite a slight dip in the daily price, the stock’s medium- and long-term indicators reveal a complex interplay of bullish and bearish signals, prompting a reassessment of its near-term outlook.

Neuland Laboratories Ltd has seen its investment rating upgraded from Hold to Buy, reflecting significant improvements across quality, valuation, financial trends, and technical indicators. This upgrade, effective from 1 June 2026, comes amid robust quarterly results, sustained long-term growth, and a shift to bullish technical momentum, positioning the small-cap pharmaceutical firm favourably against market benchmarks.

Neuland Laboratories Ltd has exhibited a notable shift in technical momentum, transitioning from a sideways trend to a bullish stance. Supported by a strong MarketsMOJO Mojo Score upgrade to 77.0 and a Buy grade, the small-cap pharmaceutical player is demonstrating robust price action and technical signals that suggest sustained upward potential.

The 50-day moving average has crossed above the 200-day moving average for Neuland Laboratories Ltd, signalling a golden cross on 1 Jun 2026. While this technical event often suggests a shift towards bullish momentum, the broader technical and fundamental context presents a nuanced picture that merits closer examination.

Neuland Laboratories Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 26 May 2026. This revision reflects a nuanced assessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. Despite robust financial performance and strong returns, evolving technical indicators and valuation metrics have prompted a more cautious stance from analysts.

Neuland Laboratories Ltd has experienced a notable shift in its technical momentum, transitioning from a mildly bullish stance to a more sideways trend. Despite a 1.88% gain on 27 May 2026, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators, prompting a downgrade in its Mojo Grade from Buy to Hold.

Neuland Laboratories Ltd is rated Buy by MarketsMOJO, with this rating last updated on 12 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Neuland Laboratories Ltd., a Hyderabad-based pharmaceutical manufacturer specialising in bulk drugs, has delivered an exceptional fourth quarter for FY26, posting a net profit of ₹212.67 crores—a staggering 424.21% surge quarter-on-quarter and 664.72% year-on-year. The ₹21,766.42-crore market cap company saw revenues soar to ₹776.25 crores in Q4 FY26, marking a 76.54% sequential jump and 136.40% annual growth. However, the stock's muted response—down 0.21% to ₹16,965.40 following the results—suggests investors are grappling with the company's elevated valuation multiples, including a price-to-earnings ratio of 123 times trailing earnings.

Neuland Laboratories Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 13 May 2026. The stock demonstrated robust investor interest, marked by a significant uptick in traded volume and value, alongside a notable upgrade in its Mojo Grade to ‘Buy’ from ‘Hold’ just days earlier.

Neuland Laboratories Ltd commenced trading on 13 May 2026 with a notable gap up, opening 8.11% higher than its previous close, signalling a robust start and positive market sentiment within the Pharmaceuticals & Biotechnology sector.

Neuland Laboratories Ltd has delivered a remarkable financial turnaround in the quarter ended March 2026, posting record revenues and operating margins that mark a significant improvement from its previous quarters. The company’s financial trend score surged from a negative -16 to a very positive 28, signalling robust operational performance and renewed investor confidence.

Neuland Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its technical outlook and institutional backing despite recent financial headwinds. The upgrade is driven primarily by improved technical indicators, stable quality metrics, and a cautious valuation stance amid mixed financial trends.